SGLT2 inhibitors for adults with sepsis
Treatments studied
Part of Infections clinical trials.
This trial tests whether a type of diabetes medicine (SGLT2 inhibitors) can help adults with sepsis, a life-threatening response to infection. If you have new-onset sepsis and can take oral medicine, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with sepsis within the last 48 hours.
- You can take medicine by mouth or through a feeding tube.
- You are willing to follow the study plan.
- You are not currently taking or have not recently taken SGLT2 inhibitors (a type of diabetes pill).
- You do not have severe kidney problems or a history of ketoacidosis (a serious diabetes complication).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called dapagliflozin can help reduce inflammation in people with sepsis (a serious blood infection that can cause organ failure). It focuses on a protein in the blood that controls inflammation and might improve recovery.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests whether a medication called dapagliflozin (normally used for diabetes and heart failure) can help improve blood flow in small vessels (microcirculation) for people in septic shock, a life-threatening condition caused by severe infection. If the medication works, it may help restore normal blood flow and improve recovery.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.